MC Services AG

🌟 Our Pick of the Final Day at BIO-Europe® 2024! 🌟 Don’t miss this wrap-up session: 🔹 11:00 – 11:45 | "Thank You for the Music": Key Takeaways from BIO-Europe 2024 (Exhibit Hall Stage) This session brings together memorable moments and fresh perspectives from the event, moderated by Millie Nelson, editor of BioXconomy, featuring insights from Cormac Sheridan. It’s a great way to reflect on the impact of this year’s discussions as we look forward to BIO-Europe 2025 in Vienna! Thank you to everyone who has been a part of BIO-Europe 2024! 📅 You can still schedule a meeting with our team today – let’s make the most of the last day: https://lnkd.in/eyDbn9z9

🌟 Final day of BIO-Europe® 2024! 🌟 As BIO-Europe® 2024 is wrapping up, we would like to thank EBD Group for organizing a wonderful conference in beautiful Stockholm! We are very glad to have been a part of a busy and inspiring conference. It was a great 30-year anniversary packed with panels, interesting and engaging meetings and a great surrounding program! We can’t wait to see you all at BIO-Europe 2025 in spring in #Milan or in autumn in #Vienna! #BIOEurope #LifeSciences #Biotech #Pharma  

"We develop our therapeutics based on inhalation, providing our drugs directly to the patient's lungs, which is the primary site of inflammation," explains Dr. Rüdiger Jankowsky, CEO of AATec Medical, at #BIOEurope2024. AATec’s innovative alpha-1-antitrypsin-(AAT)-based protein-inhalation approach aims to provide fast-acting, effective treatments for COPD, bronchiectasis, and other lung diseases, addressing urgent patient needs.   📹 Watch the interview below to learn more about AATec’s mission, or visit us on YouTube for more insights from BIO-Europe 2024: https://bit.ly/4fzvTcR

🧬 "We can measure transcription at the beginning, and this was the founding idea of the company," says Michael Bauer, Ph.D., CEO of QUANTRO Therapeutics GmbH, at BIOEurope2024. With a unique approach on precision transcriptomics and collaborations like their oncology-focused partnership with Boehringer Ingelheim, QUANTRO is bringing transcription factors within reach that were historically undruggable. 📹 Watch the interview below to learn more about QUANTRO’s innovative platform, or visit our YouTube channel for more voices from BIO-Europe Stockholm: https://bit.ly/40ywuHJ #Transcriptomics #PrecisionMedicine #Oncology

We caught up with Alexander Gebauer, Co-founder and Executive Chairman of Galimedix Therapeutics, Inc., at #BIOEurope2024 to talk with him about Galimedix's work developing innovative small molecules that target amyloid beta. 🧠 Developing novel oral and topical neuroprotective therapies aimed at treating serious eye and brain diseases, such as dry age-related macular degeneration (dAMD), glaucoma, and Alzheimer's disease, is the mission of Galimedix. Their lead candidate, GAL-101, is designed to prevent the formation of toxic amyloid beta oligomers and protofibrils, potentially altering the course of these neurodegenerative conditions. 📹 Watch the interview below to learn more about Galimedix’s vision, or visit our YouTube channel for further insights from BIO-Europe: https://bit.ly/4f8h3dA   #Ophthalmology #EyeHealth #Biotech #Pharma #Discovery

🎤 “We are growing strongly. We are looking forward to expanding our services [...] to create value sustainably and to serve and to help our partners and clients to bring medicines to the world,” says Federico Pollano, SVP Business Development, at Rentschler Biopharma, in our BIO-Europe 2024 interview. The Company's advancements in gene and cell therapy manufacturing, including lentiviral vectors (LVV), and the new production line that went operational at its US site accelerate timelines and strengthen its role as a globally trusted CDMO.   📹 Watch the interview below to learn more about Rentschler's growth strategy, or visit our YouTube channel for further insights from BIO-Europe Stockholm: https://bit.ly/48E0Vhm #RentschlerBiopharma #ReliabilityYouCanTrust #CDMO #Biotechnology #Pharma

🔍 Don’t miss out on the BIO-Europe blog article in which industry leaders explain how they are using technological innovation to drive research and achieve breakthroughs. Discover insights from companies attending the conference on how drug discovery and development platforms, AI and machine learning, MedTech, novel small molecule approaches, and more are shaping the future of biotech and pharma. Dive into the stories of biotech and pharma players who are driving success behind the scenes. Featuring insights from QUANTRO Therapeutics GmbH, Medigene AG, Secarna Pharmaceuticals, BioLizard, ARTCLINE GmbH, Rentschler Biopharma, Serum Life Science Europe GmbH, Galimedix Therapeutics, Inc. and HepaRegeniX GmbH, get a glimpse into how these companies applying the latest tech trends to tackle critical challenges in healthcare. 📖 Read more in the full article here! https://lnkd.in/exTZCZry   #BIOEurope #LifeSciences #Biotech #Pharma  

🔬 “At BioLizard, we support biotech and pharmaceutical companies with complex data analytics questions. We are capable of delivering data in an interactive and very user-friendly way to non-bioinformaticians like biologists and scientists,” says Liesbeth Ceelen, CEO of BioLizard at #BIOEurope2024. Through its newest product, Bio|Verse, the Company empowers its clients to uncover trends and actionable insights into biological data, supporting informed decision-making in the biotech industry.   📹 Watch the interview to learn more about BioLizard’s approach, or visit our YouTube channel for more perspectives from BIO-Europe in Stockholm. https://bit.ly/4hyZ8OK #DataDrivenScience #AIinBiotech #Bioinformatics #Biotechnology #Pharma

💡 "Our claim to fame is really getting from undruggable to druggable", shares Konstantin Petropoulos, CEO of Secarna Pharmaceuticals, at #BIOEurope2024. Bridging innovation with collaboration with their AI-based drug discovery platform, OligoCreator, the company identifies and characterizes proprietary and partnered oligonucleotide drug candidates in the fields of immuno-oncology, inflammatory, fibrotic and cardiometabolic diseases as well as diseases of the central nervous system and neuromuscular diseases. 📹 Watch the interview below to learn more about Secarna's vision, or visit our YouTube channel for further insights from BIO-Europe: https://bit.ly/3UFnuwx #AntisenseTherapeutics #Oligonucleotides #Biotech #Collaboration

🌟 What to Look Out for on Day Two at BIO-Europe® 2024! 🌟 BIO-Europe® continues in Stockholm with an agenda packed full of insightful sessions and cutting-edge topics, including: 🔹 09:00 – 09:45 | "Live and Learn" - Navigating Biotech's Clinical Development Challenges (Exhibit Hall Stage) Featuring Aneta Sottil, Partner at Andera Partners, this panel will dive into the biotech industry’s current challenges, from navigating clinical trial reductions to managing rising R&D complexity. Discover diverse strategies on how EU biotech can thrive in 2024. 🔹 10:00 – 10:30 | Navigating the biopharma services landscape: Current trends and future perspectives (Exhibit Hall Stage) Join Benedikt von Braunmühl, CEO of Rentschler Biopharma, for insights into the shifting biopharma services landscape. This session will cover how global events, deal-making, and regulatory advancements impact the industry, moderated by Cormac Sheridan. Don’t miss this special AI track hosted by TVM Capital Life Science with Hubert Birner: 🔹 15:30 – 16:00 “Indestructible”: Why is AI crucial for the future of the biopharma industry? (Room K1) Verena Schustereder from Google Europe will dive into AI’s transformative power in healthcare, examining its revolutionary impact on biopharma research, development, and patient care. 🔹 16:00 – 16:30 | “I Have a Dream” - AI for Drug Discovery (Room K1) Hear from top industry experts, including leaders from Flagship Pioneering, Molecular Health, and Insilico Medicine, on how AI is advancing drug discovery. This session will cover the latest advancements, challenges, and new opportunities in this dynamic field. 🔹 16:30 – 17:00 | “Why Did It Have to Be Me?” - AI for Diagnosis (Room K1) Explore the future of medical diagnostics with Prof. Ralf Huss of BioM Biotech Cluster Development GmbH and David Krummen of Vektor Medical, Inc.. Learn how AI-driven technology is enhancing diagnostic accuracy and patient outcomes in this insightful session. 🤝 Let’s connect! Visit us in the Press Lounge or book a time to meet us onsite: https://lnkd.in/eyDbn9z9 #BIOEurope #LifeSciences #Biotech #Pharma